Acute ischemic stroke management changed dramatically with endovascular thrombectomy. However, interventionalists encounter refractory vessel occlusions in nearly twenty percent of these procedures. When mechanical retrieval fails, clinicians must choose between aborting the intervention or attempting salvage revascularization. Recently, intracranial rescue stenting has emerged as a crucial bailout technique for patients with failed recanalization. In particular, a landmark multicenter study from the German Stroke Registry provides critical real-world evidence regarding its clinical efficacy and safety.

The Clinical Dilemma of Failed Endovascular Thrombectomy

Mechanical thrombectomy represents the standard of care for large vessel occlusion acute stroke. Yet, interventional teams occasionally fail to achieve adequate reperfusion despite multiple retrieval attempts. In these challenging scenarios, persistent arterial occlusion causes severe functional disability and elevated mortality. Clinicians face an agonizing procedural crossroads at the neuroangiography table. Therefore, operators must decide whether to accept persistent occlusion or pursue rescue therapies. Leaving the vessel closed frequently leads to extensive cerebral infarction and malignant cerebral edema. Conversely, aggressive additional maneuvers introduce procedural delays and potential endothelial injury. Operators historically worried about intracranial stenting due to hemorrhagic transformation risks and acute in-stent thrombosis. Furthermore, deploying permanent intracranial hardware requires potent antiplatelet medications during an acute stroke. Consequently, clinicians have debated the net clinical benefit of intracranial bailout strategies for years. Real-world registry data provide valuable guidance to resolve this difficult clinical challenge.

Evidence for Intracranial Rescue Stenting in the German Registry

The German Stroke Registry-Endovascular Treatment analyzed over fourteen thousand middle cerebral artery occlusion patients. Among these individuals, operators deployed intracranial rescue stenting in only 2.4 percent of cases. This low utilization rate demonstrates that centers currently reserve stenting as a selective salvage maneuver. Researchers matched 218 stented patients with 218 non-stented controls who had failed reperfusion. This rigorous propensity score matching accounted for baseline neurological severity, age, and vascular anatomy. Notably, patients undergoing stenting achieved significantly better functional outcomes at ninety days. The adjusted common odds ratio demonstrated a marked shift toward lower disability scores. Furthermore, successful reperfusion rates increased substantially in the stented cohort compared to conservative management. Therefore, the study confirms that intracranial stents can restore critical cerebral perfusion when thrombectomy devices fail. These multicenter findings demonstrate clear clinical efficacy across diverse real-world neurointerventional centers.

Safety Profile and Hemorrhagic Risk Considerations

Neurointerventionalists frequently express legitimate safety concerns regarding acute intracranial stenting. Specifically, antiplatelet administration during acute cerebral infarction might theoretically provoke devastating intracranial hemorrhage. However, the German Stroke Registry revealed reassuring safety outcomes between matched groups. Symptomatic intracranial hemorrhage occurred in only four percent of stented patients compared to five percent of controls. Thus, rescue stenting did not increase symptomatic bleeding risk in this large cohort. Moreover, stented patients experienced a significant reduction in malignant middle cerebral artery infarction. Malignant brain swelling occurred in only one percent of stented cases versus eight percent of controls. As a result, restoring arterial patency effectively prevented secondary herniation and life-threatening cerebral edema. Additionally, 90-day mortality decreased from thirty-seven percent in controls to twenty-six percent in stented patients. Consequently, intracranial stenting provided meaningful survival advantages without compromising neurovascular safety.

Mechanisms of Failure and Patient Selection Factors

Understanding why primary thrombectomy fails helps clinicians select optimal candidates for stenting. Underlying intracranial atherosclerotic disease represents a primary cause of refractory arterial occlusion. In Asian, African, and Hispanic populations, intracranial atherosclerosis occurs far more frequently than in Caucasian cohorts. When a catheter disrupts an atheromatous plaque, residual stenosis triggers immediate vessel reocclusion. Therefore, balloon angioplasty and stenting directly counteract vessel recoil and plaque instability. In addition, severe arterial dissection or refractory organized thrombi can frustrate standard retrieval devices. For these patients, stent deployment scaffolds the vessel wall and permanently restores downstream blood flow. However, careful patient selection remains vital before committing to permanent implant deployment. Operators must evaluate the existing ischemic core volume using advanced perfusion imaging or baseline computed tomography. Patients with vast established core infarctions derive minimal functional benefit and encounter heightened reperfusion injury. Thus, clinicians should reserve rescue stenting for individuals with viable, salvageable brain tissue.

Antiplatelet Strategies and Procedural Nuances

Acute stenting demands immediate and meticulous antiplatelet management to prevent acute in-stent thrombosis. Historically, interventionalists struggled to balance thrombosis prevention against fatal intracranial bleeding. Today, operators increasingly utilize intravenous glycoprotein IIb/IIIa inhibitors or cangrelor during acute stent delivery. These fast-acting agents offer predictable platelet inhibition with rapid reversibility if bleeding occurs. Subsequently, neurocritical care teams transition stable patients to standard dual antiplatelet oral therapy. Furthermore, device selection substantially influences procedural success during intracranial bailout. Interventionalists choose between balloon-expandable stents and self-expanding neurovascular stents based on vessel tortuosity and caliber. Balloon-expandable platforms provide excellent radial force for rigid atherosclerotic lesions. Conversely, self-expanding stents offer superior deliverability through delicate and tortuous distal neurovascular anatomy. Operators must also minimize repeated retrieval passes before deploying a rescue stent. Indeed, excessive thrombectomy passes exacerbate endothelial trauma and worsen microvascular reperfusion.

Implications for Stroke Practice and Emerging Protocols

These multicenter registry findings provide vital practice insights for comprehensive stroke centers worldwide. In India and developing nations, intracranial atherosclerotic disease accounts for a substantial proportion of ischemic strokes. Consequently, neurointerventional teams in these regions frequently encounter refractory occlusions during emergent thrombectomy. This study provides reassuring evidence supporting stenting as an effective bailout strategy rather than abandoning revascularization. Nevertheless, clinical teams must establish standardized institutional protocols to govern rescue stenting pathways. Multidisciplinary collaboration among stroke neurologists, neurointerventionalists, and neurointensivists ensures rapid decision-making at the angiography suite. Hospitals should maintain immediate access to appropriate microcatheters, intracranial stents, and intravenous antiplatelet agents. Meanwhile, ongoing randomized clinical trials will ultimately clarify optimal stent selection and drug regimens. Until trial data emerge, this real-world evidence empowers interventionalists to salvage compromised vessels and improve patient independence.

Frequently Asked Questions

What defines failed reperfusion during endovascular stroke treatment?

Interventionalists define failed reperfusion when an artery achieves a final modified Thrombolysis in Cerebral Infarction score below 2b. In these situations, mechanical thrombectomy cannot restore blood flow to at least fifty percent of the downstream vascular territory. Consequently, patients face extensive tissue infarction and poor long-term neurological recovery.

How safe is antiplatelet therapy after acute intracranial rescue stenting?

Evidence demonstrates that acute antiplatelet regimens do not significantly increase symptomatic intracranial hemorrhage rates during rescue stenting. In registry data, symptomatic bleeding occurred in four percent of stented patients versus five percent in non-stented controls. Therefore, carefully monitored intravenous antiplatelet therapy provides effective stent patency while maintaining acceptable hemorrhagic safety.

Which patients benefit most from intracranial rescue stenting?

Patients with refractory occlusions caused by underlying intracranial atherosclerosis or vascular dissection derive the greatest benefit from rescue stenting. However, candidates must possess substantial salvageable penumbral tissue on neuroimaging without extensive core infarction. Restoring arterial patency in these selected individuals prevents malignant brain edema and significantly reduces ninety-day mortality.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Healthcare professionals should make decisions based on their clinical judgment, institutional protocols, and current evidence-based practices. Refer to the latest local and national guidelines for clinical practice.

References

1. Konrad M et al. Intracranial rescue stenting in the German stroke registry: a propensity score-matched multicenter study. J Neurol. 2026 Oct 09. doi: 10.1007/s00415-026-14180-7. PMID: 42853400.
2. Rodriguez-Calienes A, Vivanco-Suarez J, Galecio-Castillo M, et al. Rescue stenting for failed mechanical thrombectomy in acute ischemic stroke: systematic review and meta-analysis. Stroke Vasc Interv Neurol. 2023;3(4):e000881. doi: 10.1161/SVIN.123.000881.
3. Sarraj A, Hassan AE, Abraham MG, et al. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. 2023;388(14):1259-1271. doi: 10.1056/NEJMoa2214403.